Antifungal Therapy

1. History of Antifungals

Kim Swindell and Emily Larkin

2. Epidemiology of Fungal Infections: What, Where, and When

Sylvia F. Costa, Fredric Lamoth and Barbara D. Alexander

3. Experimental Animal Models of Invasive Fungal Infections

Lisa Long and Chris Hager

4. Antifungal Drug Resistance: Significance and Mechanisms

Pranab K. Mukherjee, Sharvari Dharmaiah and Rania A. Sherif

5. Antifungal Prophylaxis: An Ounce of Prevention is Worth a Pound of Cure

Aimee K. Zaas

6. Preemptive Antifungal Therapy: do diagnostics help?

Kimberly E. Hanson, Vidya Jagadeesan

7. The immune response to fungal challenge

Jeffery Hu and Jeffery Aluetta

8. Immunomodulators: What is the evidence for use in mycoses?

J. Andrew Alspaugh

9. Fungal Biofilms and Catheter-Associated Infections

Jyotsna Chandra and Mahmoud Ghannoum

10. Polyenes for Prevention and Treatment Invasive Fungal Infections

Richard H. Drew

11. Flucytosine

Richard H. Drew

12. Pharmacology of Azole Antifungal Agents

Elizabeth S. Dodds Ashley

13. Echinocandins for Prevention and Treatment of Invasive Fungal Infections

Melissa D. Johnson, John Mohr and Ahmad Mourad

14. Novel Methods of Antifungal Administration

Richard H. Drew

15. Dermatophytosis

Nancy Isham and Mahmoud Ghannoum

16. Invasive Candidiasis

Rick Watkins and Tracy Lemonovich

17. Invasive Aspergillosis

Fran Esper

18. Management of Cryptococcosis

John R. Perfect and Ahmad Mourad

19. Management of Endemic Mycoses

John R. Perfect and Ahmad Mourad

20. Human Hyalohyphomycoses: A Review of Human Infections Due to Acremonium spp., Paecilomyces spp., Penicillium spp., Talaromyces spp. and Scopulariopsis spp.

Nour Hasan

21. Management of Phaeohyphomycosis

John R. Perfect and Ahmad Mourad

22. Pneumocystis

Kim Swindell

23. Management of Mucormycoses

John R. Perfect and Ahmad Mourad

24. Antifungal Management in Risk Groups: Solid Organ Transplant Recipients

Jasmine Chung, Sylvia F. Costa and Barbara D. Alexander

25. Prophylaxis and Treatment of Invasive Fungal Infections in Neutropenic Cancer and Hematopoietic Cell Transplant Patients

Hillard Lazaras, Marcie L. Riches and Daniel R. Richardson

26. Antifungal Use in Transplant Recipients: Selection, Administration and Monitoring

Richard H. Drew

27. Infants: Yeasts are Beasts in Early Life

Daniel Benjamin Jr. and Rachel Greenberg

28. Newer Antifungal Agents in PediatricsNewer Antifungal Agents in Pediatrics

William J. Steinbach

29. Fungal Infections in Burn Patients

Nour Hasan

30. Allergic Bronchopulmonary Aspergillosis

Nour Hasan

31. Fungal Infections of the Genitourinary Tract

Raymond Rackley and Cristina Rackley

32. Mycobiome in Health and Disease

Najla El-Jurdi, Pranab Mukerjee and M Ghannoum

This new edition of Antifungal Therapy aims at providing concise, practical, need-to-know information for busy physicians dealing with fungal infections, such as infectious disease physicians, transplant surgeons, dermatologists, and intensivists, as well as basic scientists and pharmaceutical company researchers interested in the state of antifungal therapy. It provides a comprehensive, up-to-date overview of the pertinent issues pertaining to antifungal treatment including the basics of clinical mycology, management insights for various infections, evidence-based treatment recommendations, and helpful tables summarizing currently available pharmacokinetics data.

Key Features

• Features useful information on administration, dosage and pharmacology of antifungal drugs that can be difficult to use in clinical practice
• Contains common Clinical Questions & Answers to highlight frequently encountered patient issues
• Covers clinical mycology essentials in addition to antifungal treatment to create a well-rounded reference
• Presents illustrations and clinical photos in full color to elucidate the concepts
• Provides detailed evidence of treatment recommendations

Mahmoud Ghannoum, Ph.D., MBA, FIDSA, joined Case Western Reserve University and University Hospitals Case Medical Center in 1996 from prior positions at the UCLA School of Medicine and Kuwait University. Dr. Ghannoum has spent his entire academic career studying medically important fungi encompassing different fungal pathogens including Candida, Aspergillus and Cryptococcus, the major causes of fungal infections. He published more than 250 peer-reviewed articles addressing various aspects of superficial and systemic fungal infections. Recently he published the first study describing the oral mycobiome of health individuals. He has published extensively in the area of fungal pathogenesis with special focus on virulence factors including phospholipase B, germination, adhesion, and biofilm formation, both in vitro and in vivo. Dr. Ghannoum is a Professor and Director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Case Medical Center. The center of excellence he directs is a multidisciplinary center that combines basic and translational research investigating fungi from the test tube to the bedside. He has performed several studies investigating the mechanisms underlying Candida pathogenesis. He is the recipient of the Freedom to Discover Award from Bristol-Myers Squibb, the Billy Cooper Award from the Medical Mycological Society of the Americas. In 2009 he was appointed as the Chairman of the Subcommittee on Antifungal Susceptibility Testing, Clinical Laboratory Standards Institute. In 2013, he was appointed as an Advisor to the CLSI Consensus Microbiology Committee, and was selected as “Most Interesting Person” by Cleveland Magazine. Dr. Ghannoum has been involved in preclinical and clinical studies evaluating the efficacy of antifungals. He has in-depth interest and expertise in oral complications of HIV/AIDS, particularly oral candidiasis, and acted as the Chair of the Oral HIV-AIDS Research Alliance (OHARA) and the PI of OHARA’s Medical Mycology Unit based at Case. Dr. Ghannoum has been involved in characterizing the oral microbiome in health and disease, specifically pioneering characterization of the human mycobiome (the fungal component of the human microbiota that make up the normal flora in HIV patients). This research may identify relationships between fungal species and their effect on various human diseases.

John R. Perfect, MD, is Professor of Medicine at Duke University Medical Center, Durham, North Carolina, Associate Professor of Microbiology, Duke University Medical Center, a faculty member of the Duke University Interdisciplinary Program in Genetics, and Director of the Duke University Mycology Research Unit. Dr. Perfect is a diplomat of the American Board of Internal Medicine and American Board of Infectious Diseases. After receiving an undergraduate degree in biology from Wittenberg University, Dr. Perfect went on to receive a medical degree from the Medical College of Ohio at Toledo. He then completed an internship at the Riverside Methodist Hospital in Columbus, Ohio; a residency in internal medicine at the University of Michigan Medical Center in Ann Arbor; and a fellowship in infectious diseases at Duke University Medical Center. A past-Fellow and member of the American Society for Microbiology and the Infectious Diseases Society of America, Dr. Perfect is also a member of the American Federation of Clinical Research, International Society for Human and Animal Mycology, and Immunocompromised Host Society. He is on the editorial boards of Infectious Diseases in Clinical Practice, Infection and Immunity, and Expert Reviews of Antifungal Therapy, and is Associate Editor of Antifungal Drug Resistance Update. Dr. Perfect has served on numerous committees and advisory boards. He is also the author of more than 300 articles and more than 250 abstracts, editorials, and letters. Dr. Perfect’s research interests focus on the understanding of fungal pathogenesis through the study of Cryptococcus neoformans as well as clinical studies on the epidemiology, diagnosis, and management of invasive mycoses.